Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

计划入组 28 人 · 首次发布于 2012 年 1 月 25 日

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

计划入组 35 人 · 首次发布于 2018 年 6 月 15 日

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

计划入组 40 人 · 首次发布于 2023 年 4 月 7 日

Glioma (NeuExcell Therapeutics)

Glioma (Neuregen Biopharm)

neoadjuvant glioma vaccine

Genomas, Inc.

United States

BioMAS Ltd.

Israel

FDA Approves Vorasidenib as Targeted Therapy for IDH-Mutant Gliomas

Vorasidenib Offers Targeted Treatment for IDH-Mutant Low-Grade Gliomas

Vorasidenib Shows Promise as First Targeted Therapy for IDH-Mutant Low-Grade Gliomas